Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 12, pp 1637–1645

Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results

Review

Abstract

Background

Advanced and recurrent ovarian cancer results in extensive spread of tumor on the peritoneal surfaces of the abdomen and pelvis. We collectively review studies in the literature that report the efficacy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer peritoneal carcinomatosis.

Methods

An electronic search of all relevant studies published in peer-reviewed journals before May 2009 was performed on three databases. The quality of each study was independently assessed and classified according to the time point of HIPEC use in various setting of ovarian cancer from the consensus statement of the Peritoneal Surface Oncology Group. Clinical efficacy was synthesized through a narrative review with full tabulation of the results of each included study.

Results

Nineteen studies each of more than ten patients reporting treatment results of HIPEC of patients with both advanced and recurrent ovarian cancer were included and data were extracted. All studies were observational case series. The overall rate of severe perioperative morbidity ranged from 0 to 40% and mortality rate varied from 0 to 10%. The overall median survival following treatment with HIPEC ranged from 22 to 64 months with a median disease-free survival ranging from 10 to 57 months. In patients with optimal cytoreduction, a 5-year survival rate ranging from 12 to 66% could be achieved.

Conclusion

Despite the heterogeneity of the studies reviewed, current evidence suggest that complete CRS and HIPEC may be a feasible option with potential benefits that are comparable with the current standard of care. A randomized trial is required to establish the role of HIPEC in ovarian cancer.

Keywords

Ovarian cancer Peritoneal neoplasm Hyperthermia Cytoreductive surgery Intraperitoneal chemotherapy Hyperthermic intraperitoneal chemotherapy 

References

  1. Abu-Hijleh MF, Habbal OA, Moqattash ST (1995) The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 186:453–467PubMedGoogle Scholar
  2. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N et al (2003) Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14(7):1094–1099PubMedCrossRefGoogle Scholar
  3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43PubMedCrossRefGoogle Scholar
  4. Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY et al (2007) Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 106(1):193–200PubMedCrossRefGoogle Scholar
  5. Bereder J, Glehen O, Habre J, Desantis M, Cotte E, Mounier N et al (2009) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. J Clin Oncol 27(15s):abstr 5542Google Scholar
  6. Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103(3):1070–1076PubMedCrossRefGoogle Scholar
  7. Bristow RE, Lagasse LD, Karlan BY (1996) Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 78(10):2049–2062PubMedCrossRefGoogle Scholar
  8. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259PubMedCrossRefGoogle Scholar
  9. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metast Rev 22:465–472CrossRefGoogle Scholar
  10. Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M et al (2000) Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 74(1):41–44PubMedCrossRefGoogle Scholar
  11. Chatzigeorgiou K, Economou S, Chrysafis G, Dimasis A, Zafiriou G, Setzis K et al (2003) Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Z Gynäkol 125(10):424–429CrossRefGoogle Scholar
  12. Chua TC, Liauw W, Robertson G, Chia WK, Soo KC, Alobaid A et al (2009a) Towards randomized trials of peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol, EpubGoogle Scholar
  13. Chua TC, Yan TD, Saxena A, Morris DL (2009b) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg, EpubGoogle Scholar
  14. Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F et al (2007) Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31(9):1813–1820PubMedCrossRefGoogle Scholar
  15. de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J et al (2003) Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 23(3c):3019–3027PubMedGoogle Scholar
  16. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113(2):315–325PubMedCrossRefGoogle Scholar
  17. Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A et al (2009) Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113(3):335–340PubMedCrossRefGoogle Scholar
  18. Ferrandina G, Ludovisi M, De Vincenzo R, Salutari V, Lorusso D, Colangelo M et al (2007) Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 18(8):1348–1353PubMedCrossRefGoogle Scholar
  19. Goff BA, Mandel L, Muntz HG, Melancon CH (2000) Ovarian carcinoma diagnosis. Cancer 89(10):2068–2075PubMedCrossRefGoogle Scholar
  20. Gori J, Castano R, Toziano M, Habich D, Staringer J, De Quiros DGB et al (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15(2):233–239PubMedCrossRefGoogle Scholar
  21. Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M et al (2009) Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol 9(7):14CrossRefGoogle Scholar
  22. Helm CW, Randall-Whitis L, Martin RS III, Metzinger DS, Gordinier ME, Parker LP et al (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105(1):90–96PubMedCrossRefGoogle Scholar
  23. Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M (2008) Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 98:283–290PubMedCrossRefGoogle Scholar
  24. Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58Google Scholar
  25. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66PubMedCrossRefGoogle Scholar
  26. Look M, Chang D, Sugarbaker PH (2004) Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 14:35–41Google Scholar
  27. Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K et al (2006) Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J Obstet Gynaecol Res 32(6):580–587PubMedCrossRefGoogle Scholar
  28. Ozols RF (2002) Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 20(5):1161–1163PubMedGoogle Scholar
  29. Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15(suppl 1):3–11PubMedCrossRefGoogle Scholar
  30. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM (2009) Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer—12-year single center experience. Eur J Surg Oncol (in press)Google Scholar
  31. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699–4707PubMedCrossRefGoogle Scholar
  32. Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2(21)Google Scholar
  33. Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F et al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32(6):671–675PubMedCrossRefGoogle Scholar
  34. Reichman TW, Cracchiolo B, Sama J, Bryan M, Harrison J, Pliner L et al (2005) Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 90(2):51–56 (discussion 56–58)PubMedCrossRefGoogle Scholar
  35. Rowan K (2009) Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Inst, EpubGoogle Scholar
  36. Rufian S, Munoz-Casares FC, Briceno J, Diaz CJ, Rubio MJ, Ortega R et al (2006) Radical surgery–peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94(4):316–324PubMedCrossRefGoogle Scholar
  37. Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94(2):325–332PubMedCrossRefGoogle Scholar
  38. Salani R, Santillan A, Zahurak ML, Giuntoli RL II, Gardner GJ, Armstrong DK et al (2007) Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109(4):685–691PubMedCrossRefGoogle Scholar
  39. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260PubMedGoogle Scholar
  40. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42PubMedCrossRefGoogle Scholar
  41. Sugarbaker PH (1996) Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer, BostonGoogle Scholar
  42. Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth 23(5):431–442CrossRefGoogle Scholar
  43. Trimble EL, Christian MC (2008) National Cancer Institute—United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 18(suppl 1):26–28PubMedCrossRefGoogle Scholar
  44. Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T et al (2008) EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC–IV ovarian, fallopian tube and peritoneal cancer (OVCA). Paper presented at the 12th Biennial Meeting International Gynecologic Cancer Society—IGCS, Bangkok, ThailandGoogle Scholar
  45. Walker JL (2009) Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol 112(3):439–440PubMedCrossRefGoogle Scholar
  46. Walker JL, Armstrong DK, Huang HQ, Fowler JM, Webster K, Burger RA et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 100:27–32Google Scholar
  47. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(24):3621–3627PubMedCrossRefGoogle Scholar
  48. Witkamp AJ, De Bree E, Van Goethem AR, Zoetmulder FAN (2001) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27:365–374PubMedCrossRefGoogle Scholar
  49. Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24(24):4011–4019PubMedCrossRefGoogle Scholar
  50. Yan TD, Black D, Savady R, Sugarbaker PH (2007a) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14(2):484–492PubMedCrossRefGoogle Scholar
  51. Yan TD, Welch L, Black D, Sugarbaker PH (2007b) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834PubMedCrossRefGoogle Scholar
  52. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P et al (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040–1045PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Terence C. Chua
    • 1
  • Greg Robertson
    • 2
  • Winston Liauw
    • 3
  • Rhonda Farrell
    • 2
  • Tristan D. Yan
    • 1
  • David L. Morris
    • 1
  1. 1.Department of Surgery, St George HospitalUniversity of New South WalesSydneyAustralia
  2. 2.Department of Gynaecology OncologySt George HospitalSydneyAustralia
  3. 3.Cancer Care CentreSt George HospitalSydneyAustralia

Personalised recommendations